Abstract
In this short review attention is drawn to promising new drugs and to promising new information on old drugs. The information may concern clinical results or pertain to preclinical data. The selection of drugs is arbitrary and no claim of completeness of listing is made. Hormones have not been considered. for which chemotherapy is poor today, such as neuroblastoma, uterus cervix cancer, larynx tumours, and chronic myeloid leukaemia blastic crisis. De Barbieri et al. (1977) are developing a large series of di-(2-chloroethyl) glycopeptides, some of which give promising resuits on sarcoma 180 and L1210 leukaemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
